CONCLUSIONS: This CEUS-based nomogram provides an accurate, noninvasive method for predicting GPC-3 expression and RFS in HCC patients, serving as a valuable tool for personalized treatment strategies and optimizing GPC-3-targeted therapies. This evidence concerns the gene GPC3 and hepatocellular carcinoma.